Insider information

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

You are here: epigenomics > News & Investors > Insider information

Insider information

19. September 2022 - 0:00 (CEST)

Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs

Read more

09. September 2022 - 0:00 (CEST)

Epigenomics AG: Capital reduction planned at a ratio of 4 : 1

Read more

20. August 2021 - 0:00 (CEST)

Epigenomics AG: Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share

Read more

Press releases

09. November 2022

Epigenomics AG reports financial results for the first nine months 2022

Read more

19. September 2022

Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

Read more

15. August 2022

Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG

Read more